1st Quarter - Report

TARPLIN, DOWNS & YOUNG, LLC for JAZZ PHARMACEUTICALS INC.

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
$60,000
Expenses
—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report (this page) Apr 18, 2014 $60,000 Replaced
1st Quarter - Amendment Jan 4, 2017 $60,000 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

PL 112-144 - The Food and Drug Administration Safety and Innovation Act, implementation H.R. 4069 - Ensuring Patient Access and Effective Drug Enforcement Act of 2013 ***, no specific bills, drug safety

LobbyistCovered position, as disclosed
RAISSA H DOWNS Prin. Dep. Asst. Sec. for Leg. - HHS; Dep. Asst.
MICHELLE P EASTON Chief Health Counsel, Sen. Cmte. on Finance;
ISAAC A FORDJOUR —
LINDA E TARPLIN Congressman Billy Tauzin
JENNIFER B YOUNG Asst. Sec. for Leg. - HHS; Dep. Asst. Sec. for Leg.

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 4069 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.